1
|
Al-Hosary A, Radwan AM, Ahmed LS, Abdelghaffar SK, Fischer S, Nijhof AM, Clausen PH, Ahmed JS. Isolation and propagation of an Egyptian Theileria annulata infected cell line and evaluation of its use as a vaccine to protect cattle against field challenge. Sci Rep 2024; 14:8565. [PMID: 38609410 PMCID: PMC11014843 DOI: 10.1038/s41598-024-57325-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2023] [Accepted: 03/18/2024] [Indexed: 04/14/2024] Open
Abstract
Tropical theileriosis is an important protozoan tick-borne disease in cattle. Vaccination using attenuated schizont-infected cell lines is one of the methods used for controlling the disease. This study describes the production of attenuated schizont-infected cell lines from Egypt and an evaluation of its use as a vaccine to protect calves against clinical disease upon field challenge. Two groups of exotic and crossbred male calves were divided into vaccinated and control groups. The vaccinated groups were inoculated with 4 ml (1 × 106 cells/ml) of the attenuated cell line. Three weeks after vaccination, calves of both groups were transported to the New Valley Governorate (Egyptian oasis) where they were kept under field conditions and exposed to the natural Theileria annulata challenge. All animals in the control group showed severe clinical signs and died despite treatment with buparvaquone, which was administered after two days of persistent fever due to a severe drop in packed cell volume (PCV). Animals in the vaccinated group became seropositive without developing severe clinical signs other than transient fever. Post-mortem examinations revealed enlarged and fragile lymph nodes, spleen, and liver with necrosis and hemorrhages. These findings indicate that the Egyptian attenuated cell line was successful in protecting both exotic and crossbred animals against tropical theileriosis under field conditions.
Collapse
Affiliation(s)
- Amira Al-Hosary
- Department of Animal Medicine (Infectious Diseases), Faculty of Veterinary Medicine, Assiut University, Assiut, 71526, Egypt.
| | - Ahmed M Radwan
- Field Veterinarian, EL-Minia's Veterinary Directorate, EL-Minia, Egypt
| | - Laila S Ahmed
- Department of Animal Medicine (Infectious Diseases), Faculty of Veterinary Medicine, Assiut University, Assiut, 71526, Egypt
| | - Sary Kh Abdelghaffar
- Department of Pathology and Clinical Pathology, Faculty of Veterinary Medicine, Assiut University, Assiut, 71526, Egypt
- Department of Pathology and Clinical Pathology, School of Veterinary Medicine, Badr University in Assiut, Assiut, Egypt
| | - Susanne Fischer
- Institute of Infectology, Friedrich-Loeffler-Institut, Südufer 10, Insel Riems, 17943, Greifswald, Germany
| | - Ard M Nijhof
- Institute of Parasitology and Tropical Veterinary Medicine, Freie Universität Berlin, 14163, Berlin, Germany.
- Veterinary Center for Resistance Research, Freie Universität Berlin, 14163, Berlin, Germany.
| | - Peter-Henning Clausen
- Institute of Parasitology and Tropical Veterinary Medicine, Freie Universität Berlin, 14163, Berlin, Germany
| | - Jabbar S Ahmed
- Institute of Parasitology and Tropical Veterinary Medicine, Freie Universität Berlin, 14163, Berlin, Germany
| |
Collapse
|
2
|
Contreras C, Alegría-Moran R, Duchens M, Ábalos P, López R, Retamal P. Specific and non-specific effects of Mycobacterium bovis BCG vaccination in dairy calves. Front Vet Sci 2023; 10:1278329. [PMID: 37869491 PMCID: PMC10588636 DOI: 10.3389/fvets.2023.1278329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Accepted: 09/18/2023] [Indexed: 10/24/2023] Open
Abstract
Bovine tuberculosis (bTB) is a chronic disease mainly caused by Mycobacterium bovis, a zoonotic pathogen with economic significance as it leads to reduced milk and meat production, and high costs for control measures. The Bacillus Calmette-Guérin (BCG) vaccine, primarily used to prevent tuberculosis in humans, has also been studied for controlling bTB. While showing effectiveness in preventing M. bovis infection and disease in cattle, the BCG vaccine can induce non-specific effects on the immune system, enhancing responses to infections caused by unrelated pathogens, and also having non-specific effects on lactation. The aim of this study is to describe both the specific and non-specific effects of BCG vaccination in calves from a commercial dairy herd in central Chile. Diagnosis of M. bovis infection was performed through the IFNγ release assay (IGRA) using ESAT6/CFP-10 and Rv3615c antigens. The records of milk production, somatic cell count (SCC), clinical mastitis (CM) and retained placenta (RP) during the first lactation were compared between vaccinated and non-vaccinated animals. The breed (Holstein Friesian [HF] v/s HF × Swedish Red crossbred [HFSR]) and the season (warm v/s cold) were also analyzed as categorical explanatory variables. Results of IGRA showed significant differences between vaccinated and control groups, indicating a vaccine efficacy of 58.5% at 18 months post vaccination in HFSR crossbred animals. Although milk production did not vary, SCC and CM showed differences between groups, associated to the breed and the season, respectively. When analyzing CM and RP as a whole entity of disease, BCG showed protection in all but the cold season variables. Overall, the BCG vaccine induced protective specific and non-specific effects on health parameters, which may be influenced by the breed of animals and the season. These results provide new features of BCG protection, supporting initiatives for its implementation as a complementary tool in bTB control.
Collapse
Affiliation(s)
- Catalina Contreras
- Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile
| | - Raúl Alegría-Moran
- Escuela de Medicina Veterinaria, Sede Santiago, Facultad de Recursos Naturales y Medicina Veterinaria, Universidad Santo Tomás, Santiago, Chile
| | - Mario Duchens
- Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile
| | - Pedro Ábalos
- Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile
| | - Renata López
- Magister en Ciencias Animales y Veterinarias, Universidad de Chile, Santiago, Chile
| | - Patricio Retamal
- Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile
| |
Collapse
|
3
|
Williams GA, Scott-Baird E, Núñez A, Salguero FJ, Wood E, Houghton S, Vordermeier HM. The safety of BCG vaccination in cattle: results from good laboratory practice safety studies in calves and lactating cows. Heliyon 2022; 8:e12356. [PMID: 36590473 PMCID: PMC9800532 DOI: 10.1016/j.heliyon.2022.e12356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Revised: 10/17/2022] [Accepted: 12/07/2022] [Indexed: 12/23/2022] Open
Abstract
Bovine tuberculosis (bTB) is a global disease of livestock that has damaging economic, animal health and public health consequences. Conventional bTB disease control strategies, based around the testing and slaughter of cattle infected with bTB, are typically used to help limit or reduce the transmission of this disease but in many low- and middle-income countries such strategies may often be economically unviable, culturally unacceptable or logistically impracticable. The use of vaccination to protect cattle against bTB could provide a potentially more affordable, ethically acceptable and practical additional disease control measure. The protective efficacy of the commercially produced and readily available human vaccine against tuberculosis (Mycobacterium bovis Bacille Calmette-Guérin; BCG) in cattle has been demonstrated in many experimental laboratory and field studies. However, Good Laboratory Practice (GLP) studies assessing the safety of BCG vaccination in cattle have not previously been reported. We describe here the results of two GLP safety studies in which calves and lactating cows were vaccinated with BCG (Danish 1331 strain). From an animal health and welfare perspective, the results of these studies indicate that BCG vaccine is well tolerated in these categories of cattle with only transient and minor local or systemic reactions. Furthermore, there was no evidence that BCG was shed in raw milk, saliva or faeces collected from vaccinates and vaccination did not have a detrimental effect on milk yields in lactating cattle. These data, underpinned by GLP principles, further support the existing data on the safety of BCG vaccine in cattle and complement the abundant available cattle efficacy data for this potential cattle bTB vaccine.
Collapse
Affiliation(s)
- Gareth A. Williams
- Animal and Plant Health Agency (APHA), Addlestone, Surrey, KT15 3NB, UK,Corresponding author.
| | | | - Alejandro Núñez
- Animal and Plant Health Agency (APHA), Addlestone, Surrey, KT15 3NB, UK
| | | | - Emma Wood
- Queens Hall, Narberth, Pembs, SA67 7AS, UK
| | - Steve Houghton
- Veterinary Vaccines Consultancy Ltd, Paulerspury, Northants, NN12 7NN, UK
| | | |
Collapse
|
4
|
Manohar MM, Campbell BE, Walduck AK, Moore RJ. Enhancement of live vaccines by co-delivery of immune modulating proteins. Vaccine 2022; 40:5769-5780. [PMID: 36064671 DOI: 10.1016/j.vaccine.2022.08.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 06/23/2022] [Accepted: 08/16/2022] [Indexed: 11/25/2022]
Abstract
Vaccines are very effective in providing protection against many infectious diseases. However, it has proven difficult to develop highly efficacious vaccines against some pathogens and so there is a continuing need to improve vaccine technologies. The first successful and widely used vaccines were based on attenuated pathogens (e.g., laboratory passaged Pasteurella multocida to vaccinate against fowl cholera) or closely related non-pathogenic organisms (e.g., cowpox to vaccinate against smallpox). Subsequently, live vaccines, either attenuated pathogens or non-pathogenic microorganisms modified to deliver heterologous antigens, have been successfully used to induce protective immune responses against many pathogens. Unlike conventional killed and subunit vaccines, live vaccines can deliver antigens to mucosal surfaces in a similar manner and context as the natural infection and hence can often produce a more appropriate and protective immune response. Despite these advantages, there is still a need to improve the immunogenicity of some live vaccines. The efficacy of injectable killed and subunit vaccines is usually enhanced using adjuvants such mineral salts, oils, and saponin, but such adjuvants cannot be used with live vaccines. Instead, live vaccines can be engineered to produce immunomodulatory molecules that can stimulate the immune system to induce more robust and long-lasting adaptive immune responses. This review focuses on research that has been undertaken to engineer live vaccines to produce immunomodulatory molecules that act as adjuvants to increase immunogenicity. Adjuvant strategies with varying mechanisms of action (inflammatory, antibody-mediated, cell-mediated) and delivery modes (oral, intramuscular, intranasal) have been investigated, with varying degrees of success. The goal of such research is to define adjuvant strategies that can be adapted to enhance live vaccine efficacy by triggering strong innate and adaptive immune responses and produce vaccines against a wider range of pathogens.
Collapse
Affiliation(s)
- Megha M Manohar
- School of Science, RMIT University, Bundoora, Victoria 3083, Australia.
| | | | - Anna K Walduck
- School of Science, RMIT University, Bundoora, Victoria 3083, Australia.
| | - Robert J Moore
- School of Science, RMIT University, Bundoora, Victoria 3083, Australia.
| |
Collapse
|
5
|
Fish EN, Benn CS, Klein SL. Introduction. Vaccine 2022; 40:1513-1515. [DOI: 10.1016/j.vaccine.2022.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|